This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
BackgroundThe left subclavian artery (LSA) can be intentionally covered by a stent graft to acquire adequate landing zones for a proximal entry tear near the LSA during thoracic endovascular aortic repair (TEVAR). The Castor single-branched stent graft is designed to treat type B aortic dissection (TBAD) to retain the LSA during TEVAR.
Stroke, Volume 56, Issue Suppl_1 , Page ADP36-ADP36, February 1, 2025. All patients had headache, and funduscopic examination demonstrated papilledema for all patients. All patients had headache, and funduscopic examination demonstrated papilledema for all patients. Additional randomized and controlled clinical research is deserved.
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. Admission National Institutes of Health Stroke Scale (NIHSS) 20. XIENCE Skypoint™ stent was deployed within the left vertebral artery (V4 segment) with restoration of flow preceded by eptifibatide drip (Fig 2).
These results were driven mainly by the reduction in repeat vessel revascularisation, stroke and stentthrombosis. Conclusion Colchicine significantly reduced the risk of MACE in patients with CAD who underwent PCI, mostly in the reduction of repeat vessel revascularisation, stroke and stentthrombosis.
Stroke: Vascular and Interventional Neurology, Volume 3, Issue 6 , November 1, 2023. BackgroundProcedural intravenous cangrelor has been proposed as an effective platelet inhibition strategy for stenting in acute ischemic stroke. Similarly, the rate of in‐stentthrombosis was not significantly different between the 2 groups (1.8%
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. Seven patients had strokes of any kind, three of which were unrelated to the treatment territory, and two of the remaining 4 were non‐compliant with antiplatelet therapy. One patient had a new intraparenchymal hemorrhage, but no appreciable deficit.
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionCarotid webs (CaW) have been increasingly recognized as a unique cause of recurrent ischemic strokes.1 of patients with acute ischemic stroke. The prevalence of CaWs has been reported to be between 1.2%
All the patients were observed during their hospital stay for postprocedure in-hospital morbidity (pump failure, contrast-induced nephropathy, major bleeding, cerebrovascular accident/stroke, access site complications or stentthrombosis) and mortality. The mean BMI was 27.48±4.93
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. She was noted to have incidental left internal jugular (IJ) vein thrombosis for which anticoagulation was held in the setting of recent neurosurgical procedure and SAH. Cerebral vasospasm following EEA has rarely been described.
Background Stentthrombosis (ST) is an uncommon but serious complication of stent implantation. Methods The analysis included patients who received stent placement for the index acute coronary syndrome (ACS). drug-eluting stent (DES) vs. bare-metal stent (BMS) and anticoagulant with rivaroxaban vs. placebo].
3.30]) and subacute definite or probable stentthrombosis (0.58% and 0.17%; hazard ratio, 3.40 [95% CI, 1.26–9.23]) years; men, 76.6%; acute coronary syndrome, 75.0%). There was no difference in net adverse clinical outcomes and each component of coprimary cardiovascular end point.
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. In order to improve treatment outcomes in these difficult cases, the use of stent‐assisted embolization has been attempted in endovascular treatment of intracranial aneurysms.
Background:Stopping aspirin within 1 month after implantation of a drug-eluting stent (DES) for ticagrelor monotherapy has not been exclusively evaluated for patients with acute coronary syndrome (ACS). Circulation, Ahead of Print. versus 3.4%; HR, 0.35 [95% CI, 0.20–0.61];P<0.001).Conclusions:This 0.61];P<0.001).Conclusions:This
However, there are shortcomings associated with LVAD implantation: complications include infection, blood clotting (thrombosis), stroke and bleeding. A novel flexible stented blood inlet will conform to the shape of the patient’s heart to prevent flow stasis and clotting.
There was also no difference in the rate of bleeding between PFT-guided and standard therapies (major bleeding: RR=0.97, p=0.78, minor bleeding: RR=0.89, p=0.19 and any bleeding: RR=1.04, p=0.33).
The primary outcome was major adverse cardiac and cerebrovascular event (MACCE), namely a composite of death from cardiovascular causes, myocardial infarction (MI), stroke, stentthrombosis within 12 month. The secondary outcome was Bleeding Academic Research Consortium (BARC) scale bleeding events within 12 months.
The primary efficacy objective was to demonstrate superiority of PPA to reduce the primary efficacy end point of all-cause death, nonfatal myocardial infarction, nonfatal stroke, stentthrombosis (definite), or urgent revascularization (any vessel) within 30 days.
vs 6.0%), stroke (RR=1.02; 95% CI [0.38, 2.75]; p =0.97; 2.0% vs 13.6%), any stentthrombosis (RR=1.42; 95% CI [0.35, 5.72]; p=0.62; 2.2% vs 6.0%), stroke (RR=1.02; 95% CI [0.38, 2.75]; p =0.97; 2.0% vs 13.6%), any stentthrombosis (RR=1.42; 95% CI [0.35, 5.72]; p=0.62; 2.2%
In the early years of percutaneous coronary intervention (PCI), studies indicated a heightened risk of major adverse cardiac events (MACE) in patients with reduced left ventricular ejection fraction (LVEF), involving outcomes such as death, Q-wave myocardial infarction (MI), stentthrombosis, and repeat revascularization.
The primary endpoint consisted of a composite of all-cause mortality, MI, stroke, coronary revascularization, or hospitalization for unstable angina. The primary non-inferiority endpoint was MACCE (a composite of cardiac death, MI, ischaemic stroke, stentthrombosis, or target vessel revascularisation).
This can lead to a transient ischemic attack (TIA) or stroke. Deep Vein Thrombosis (DVT) : A blood clot occurring in a deep vein. Causes include infection, malignancy, surgery, scar tissue formation, trauma, deep vein thrombosis (DVT), radiation or other cancer treatment. Damaged valves within the veins cause this.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
52 
Let's personalize your content